about
Eag and HERG potassium channels as novel therapeutic targets in cancerAnoctamin/TMEM16 family members are Ca2+-activated Cl- channelsEag1 channels as potential early-stage biomarkers of hepatocellular carcinomaHuman EAG channels are directly modulated by PIP2 as revealed by electrophysiological and optical interference investigationsCalmodulin Regulates Human Ether à Go-Go 1 (hEAG1) Potassium Channels through Interactions of the Eag Domain with the Cyclic Nucleotide Binding Homology DomainBehavioural and functional characterization of Kv10.1 (Eag1) knockout micePositive correlation between the expression of hEag1 and HIF-1α in breast cancers: an observational study.The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemiaTranscriptional and post-transcriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel.Targeting potassium channels in cancerPotassium channel ether à go-go1 is aberrantly expressed in human liposarcoma and promotes tumorigenesisIn vivo dual targeting of the oncogenic Ether-à-go-go-1 potassium channel by calcitriol and astemizole results in enhanced antineoplastic effects in breast tumors.Regulation of hERG and hEAG channels by Src and by SHP-1 tyrosine phosphatase via an ITIM region in the cyclic nucleotide binding domainCancer as a channelopathy: ion channels and pumps in tumor development and progressionAnalysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival.Overexpression of KCNJ3 gene splice variants affects vital parameters of the malignant breast cancer cell line MCF-7 in an opposing manner.The Cole-Moore Effect: Still Unexplained?Suppression of the Eag1 potassium channel sensitizes glioblastoma cells to injury caused by temozolomideAbnormal expression, localization and interaction of canonical transient receptor potential ion channels in human breast cancer cell lines and tissues: a potential target for breast cancer diagnosis and therapy.Expression profiling of ion channel genes predicts clinical outcome in breast cancer.Characterization of hERG1 channel role in mouse colorectal carcinogenesis.Ion channels as targets for cancer therapyProtons and Ca2+: ionic allies in tumor progression?Ion channels in postnatal neurogenesis: potential targets for brain repair.Eag1 channels as potential cancer biomarkers.Targeting Ca²⁺ transport in cancer: close reality or long perspective?miRNA in the regulation of ion channel/transporter expression.The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.Role of ion channels in regulating Ca²⁺ homeostasis during the interplay between immune and cancer cells.K+ channel signaling in irradiated tumor cells.EAG channels expressed in microvillar photoreceptors are unsuited to diurnal vision.Frequent aberrant expression of the human ether à go-go (hEAG1) potassium channel in head and neck cancer: pathobiological mechanisms and clinical implications.The potassium-chloride cotransporter 2 promotes cervical cancer cell migration and invasion by an ion transport-independent mechanism.The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells.Astemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCC.Placing ion channels into a signaling network of T cells: from maturing thymocytes to healthy T lymphocytes or leukemic T lymphoblasts.The role of ion channels and transporters in cell proliferation and cancer.The combination astemizole-gefitinib as a potential therapy for human lung cancer.Inducing Polyclonal Eag1-Specific Antibodies by Vaccination with a Linear Epitope Immunogen and Its Relation to Breast Tumorigenesis.Abnormal DNA methylation may contribute to the progression of osteosarcoma.
P2860
Q21245576-140A1B22-0CAE-4F5A-9FD2-8702E6F1C0C5Q24645272-8E9BFD48-F595-481A-8498-8EC17A6B57F4Q28069313-DD98B6E6-EEEC-4677-9676-5B4A68DCB581Q28118681-91D92E84-0F01-4D3A-96A1-DB4C4739F692Q28119193-66A7E1D2-F5F9-4539-BD76-7E9782E11339Q30454673-F450E848-1E9E-4FF1-8381-955ABD15B03CQ33629346-BE797444-89E1-4303-A263-BE500062D82BQ33715775-72265B17-C516-40D2-A7FA-CDB6BA96D4E5Q33927117-CEA6B464-E7DD-48AE-B470-61F1AA1AF13DQ33937726-E03EE817-A3A8-4ADA-99E3-D02F99ECCD53Q34022525-A6FFDF5C-24EE-46D6-BDA5-CB8B5133DED5Q34325900-54F77FF6-2499-4846-BE3B-66E184F05BEEQ35108594-B4356542-3C8A-4499-9B40-A73DC530BB8DQ35184108-195087DD-1ED3-42BE-B332-88BDDF2593D9Q35830894-C17E5450-3F26-4590-90EE-05C80013AC02Q36103130-95BBB9E2-EA32-4C68-B08B-C9242E50D598Q36146721-2CE029BB-AD40-47E6-AB90-1A7456C3533FQ37288597-6360E463-A102-4036-9D5F-7EAA502BDC55Q37332362-7A353981-F833-4584-BBBC-CD3CC0C4BBE4Q37361137-AB9AA1E8-783F-4E46-8026-7D7D31DF9439Q37482529-17FC67F5-86A3-47F4-A4CE-5E851C8D1BCEQ37901394-02B19F1B-652E-48D9-9064-206CF9EF1710Q37917316-839A6540-C2A0-4AB4-8689-4463E6195AA3Q38012031-F6BCACB0-DAAA-4928-B753-0733FF9BE5CBQ38025086-56979724-DA44-4D51-B4F0-591BC2E36480Q38072110-1A65CD9E-17AA-4922-80F9-5221932B2F03Q38110520-86EA42C7-5243-4A85-92B7-519E98DCB816Q38192017-B5267E6B-736D-4B0E-9C19-A94F7AE7ADB0Q38361335-23068B9C-A722-4ED1-B8CC-6B31941A047DQ38831429-A0AE9C9A-5076-43C1-97C0-22F098A4A25BQ39020841-1083604C-16EA-42AC-9EFF-62E4B9B806A8Q39371029-5B3118AF-E1F8-4646-AB49-281F502566F2Q39475047-F8F6AA8B-98A4-4343-B99F-1BE33FC73B79Q39656692-B334EE2E-0E05-4515-8B82-2D46A5DFFC9DQ41201274-B87A01A2-54C3-45E3-8535-92DF1055975EQ42061814-9FA59BA7-A68C-4B35-AC0B-1694AC241D02Q42931417-524036B2-80F2-4119-81F8-B831E038D407Q47133199-B05988CA-EA5E-4B42-B5C9-509942ECB9EDQ48016146-7960FD61-74B7-4122-A16F-A1737634384AQ49185675-884E8FAF-0F51-4ECC-8B9C-0E63179FF072
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Eag1: an emerging oncological target.
@en
Eag1: an emerging oncological target.
@nl
type
label
Eag1: an emerging oncological target.
@en
Eag1: an emerging oncological target.
@nl
prefLabel
Eag1: an emerging oncological target.
@en
Eag1: an emerging oncological target.
@nl
P1433
P1476
Eag1: an emerging oncological target
@en
P2093
Walter Stühmer
P304
P356
10.1158/0008-5472.CAN-07-5710
P407
P577
2008-03-01T00:00:00Z